Sockel, Katja
Götze, Katharina
Ganster, Christina
Bill, Marius
Georgi, Julia-Annabell
Balaian, Ekaterina
Aringer, Martin
Trautmann-Grill, Karolin
Uhlig, Maria
Bornhäuser, Martin
Haase, Detlef
Thiede, Christian
Article History
Received: 10 December 2023
Accepted: 27 December 2023
First Online: 12 January 2024
Declarations
:
: Data were collected under written informed consent (according to the principles of the Helsinki Declaration) as part of the HMA-NGS study, which has been approved by the Institutional Ethics Committee of each participating center. Both patients gave their consent to publish their data.
: KS served on advisory boards and received lecture fees from BMS/Celgene and Novartis. KSG received honoraria from BMS, Jazz Pharmaceuticals, and Abbvie. MA served on advisory boards for Novartis. MB served on advisory boards and received lecture fees from Jazz Pharmaceuticals and served on advisory boards from FarmaTrust. MB received travel compensation from DKMS. DH received research funding from BMS, Jazz Pharmaceuticals, and lecture fees from BMS/Celgene, Jazz Pharmaceuticals, and Novartis; he served on advisory boards for BMS, Novartis, Jazz Pharmaceuticals, Gilead, Takeda, and Hexal. CT is co-owner and CEO of AgenDix GmbH. CT has received lecture fees and/or participated in advisory boards from Novartis, Jazz Pharmaceuticals, Astellas, Janssen, and Illumina. CT has received research funding from Novartis and Bayer. CG, JAG, EB, and MU declare no potential conflict of interest.